Policies

Disclaimer

ASCO AI in Oncology is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO^®). The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.

AI Policy

ASCO AI in Oncology is committed to delivering accurate, informative, trustworthy, and ethical content to our readership. As ASCO AI in Oncology is an AI-focused and -forward website, we embrace all of the potential benefits of artificial intelligence (AI) use in content creation, but are also aware of the potential challenges and chances for misuse or inaccuracy. As such, while ASCO AI in Oncology supports the use of AI tools for assisting in generating and reviewing content, we also must stress that use of such tools should be transparent, ethical, and aligned with our commitment to journalistic integrity.

All articles, whether written with the assistance of AI tools or not, should have a human byline. When AI tools are used, this should be acknowledged by the author and the article should also have undergone human oversight to ensure that the authors and editors can stand by the resulting content.

This policy is intended for all physicians and health-care professionals submitting insights to ASCO AI in Oncology, but our editorial team is held to the same standards and expectations. Adjustments and refinements to this policy and others will be made as necessary to ensure that our editorial practices remain in line with our core values and journalistic standards.